ArticleFrontiers in oncology2021
Selection of Treatment Regimens for Recurrent Cervical Cancer.
Article in Frontiers in oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 46 citations in OpenAlex.
- pH-responsive Folate-PEG modified ZIF-8 Nanoparticles deliver fisetin to Aquaporin-3 for cervical cancer therapy.iScience · 2026Article
- Reirradiation for Recurrent Cervical Cancer Within the Previous Radiation Field Using a Bioabsorbable Spacer: A Case Report.The journal of obstetrics and gynaecology research · 2026Article
- Article
- Evaluation of the Frequency and Patterns of Cervical Cancer Recurrence After Treatment Using ^18F-FDG PET-CT: A Cross-Sectional Study.Health science reports · 2025Article
- Emerging Therapeutic Strategies for HPV-Related Cancers: From Gene Editing to Precision Oncology.Current issues in molecular biology · 2025Review
- Resveratrol: Sensitising CD44+ Cervical Cancer Cells to Carboplatin and Mitigating Metastasis.Cancer medicine · 2025Review
- Targeting immune microenvironment in cervical cancer: current research and advances.Journal of translational medicine · 2025Review
- The Value of the Naples Prognostic Score at Diagnosis as a Predictor of Cervical Cancer Progression.Medicina (Kaunas, Lithuania) · 2025Article
- Metastatic Brain Adenocarcinoma and Pelvic Squamous Carcinoma Originating From Cervical Adenosquamous Carcinoma: A Case Report and Literature Review.International journal of women's health · 2025Article
- Integrating cat boost algorithm with triangulating feature importance to predict survival outcome in recurrent cervical cancer.Scientific reports · 2024Article
- Observational
- Recurrent early-stage squamous cell carcinoma cervical cancer presenting with isolated ovary metastasis: a rare case report.Annals of medicine and surgery (2012) · 2023Article
- Preoperative prediction of cervical cancer survival using a high-resolution MRI-based radiomics nomogram.BMC medical imaging · 2023Article
- Comparison of PD-L1 expression and MMR status between primary and matched metastatic lesions in patients with cervical cancer.Journal of cancer research and clinical oncology · 2023Article
- Gold-Enhanced Brachytherapy by a Nanoparticle-Releasing Hydrogel and 3D-Printed Subcutaneous Radioactive Implant Approach.Advanced healthcare materials · 2023Article
- Interactions of EGFR/PTEN/mTOR-Pathway Activation and Estrogen Receptor Expression in Cervical Cancer.Journal of personalized medicine · 2023Article
- Cytotoxic Effects of Combinative ZnPcSInternational journal of molecular sciences · 2023Article
- Multimodality treatment for multiple recurrences of cervical cancer after radiotherapy: a case report.Translational cancer research · 2022Article
- Salvage high intensity focused ultrasound for residual or recurrent cervical cancer after definitive chemoradiotherapy.Frontiers in immunology · 2022Article
- The prognostic value and biological significance of gap junction beta protein 2 (GJB2 or Cx26) in cervical cancer.Frontiers in oncology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThe selection of individualized treatment for recurrent cervical cancer is challenging. This study aimed to investigate the impact of various therapies on survival outcomes after recurrence.
methodsEligible patients were diagnosed with recurrent cervical cancer between March 2012 and April 2018. Postrecurrence progression-free survival (PFS) and overall survival (OS) were investigated in the whole cohort and in subgroups, categorized by recurrence site and prior radiotherapy history, using a multivariate model that incorporated treatment for primary and recurrent tumors, histological pathology, and FIGO staging.
resultsTwo hundred and sixty recurrent cervical cancer patients were included. As of March 1, 2020, the median postrecurrence PFS and OS were 7.0 (range 0-94) and 24.0 (1.8-149.1) months, respectively. In a multivariate model measured by PFS, radiotherapy was superior to other therapies for the whole cohort (
conclusionsIn cervical cancer patients, postrecurrence radiotherapy can improve PFS and OS for patients with recurrence within the pelvic cavity and without prior radiotherapy. For recurrence beyond the pelvic cavity or cases with a history of radiotherapy, combination or individualized therapy may provide potential survival benefits.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.